BMS-354326

• CAT Number: I003048
• CAS Number: 708258-16-6
• Molecular Formula: C28H40N4O5
• Molecular Weight: 512.65
• Purity: ≥95%
• Synonyms: BMS-354326; BMS 354326; BMS354326; CHEMBL306448; BDBM50144532.;2-Azetidinecarboxylic acid, 4-oxo-1-((4-(1-oxo-6-phenylhexyl)-1-piperazinyl)carbonyl)-3-(2-(3-piperidinyl)ethyl)-, (2S,3R)-
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4 °C for short term or -20 °C for long term
• IUPAC Name: (2S,3R)-4-oxo-1-[4-(6-phenylhexanoyl)piperazine-1-carbonyl]-3-(2-piperidin-3-ylethyl)azetidine-2-carboxylic acid
• InChI: InChI=1S/C28H40N4O5/c33-24(12-6-2-5-10-21-8-3-1-4-9-21)30-16-18-31(19-17-30)28(37)32-25(27(35)36)23(26(32)34)14-13-22-11-7-15-29-20-22/h1,3-4,8-9,22-23,25,29H,2,5-7,10-20H2,(H,35,36)/t22?,23-,25+/m1/s1
• InChIKey: XVYFBYVSZOCXRJ-OMQKAAQBSA-N
• SMILES: C1CC(CNC1)CC[C@@H]2[C@H](N(C2=O)C(=O)N3CCN(CC3)C(=O)CCCCCC4=CC=CC=C4)C(=O)O

BMS-354326（Cat No.:I003048）, also known as Dasatinib, is a potent, orally active tyrosine kinase inhibitor developed for the treatment of certain cancers, particularly chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It works by inhibiting multiple kinases, including BCR-ABL, SRC family kinases, and other receptor tyrosine kinases, which play key roles in the growth and survival of cancer cells. BMS-354326 is effective in treating drug-resistant CML, particularly in cases resistant to imatinib, offering a critical therapeutic option in leukemia treatment. It is marketed under the name Sprycel.